TRIVAIR
DEAD

Serial Number

88830833

Owner

Acerus Biopharma Inc.

Attorney

Darrell G. Mottley

Filing Date

Mar 11, 2020

Add to watchlist:

No watchlists yet
View on USPTO

TRIVAIR Trademark

Serial Number: 88830833

TRIVAIR is a trademark filed by Acerus Biopharma Inc. on March 11, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently no longer active.

Owner Contact Info

Acerus Biopharma Inc.

2486 Dunwin Drive
Mississauga, Ontario L5L1J9 , CA

Entity Type: 03

Trademark Details

Filing Date

March 11, 2020

Registration Date

Not Registered

Goods & Services

Inhalers filled with pharmaceutical preparations for use in the treatment of respiratory diseases, disorders and infections; inhalers filled with pharmaceutical preparations for use in the treatment of asthma; inhalers filled with pharmaceutical preparations for use in the treatment of chronic obstructive pulmonary disease; inhalers filled with pharmaceutical preparations for use in the treatment of rhinitis; inhalers filled with pharmaceutical preparations for use in the treatment of sinus polyps; inhalers filled with pharmaceutical preparations for use in the treatment of viral airway infections; inhalers filled with pharmaceutical preparations for use in the treatment of multiple sclerosis; inhalers filled with pharmaceutical preparations for use in the treatment of depression; inhalers filled with pharmaceutical preparations for use in the treatment of epilepsy; inhalers filled with pharmaceutical preparations for use in the treatment of migraine; inhalers filled with pharmaceutical preparations for use in the treatment of Alzheimer's disease; inhalers filled with pharmaceutical preparations for use in the treatment of Parkinson's disease; inhalers filled with pharmaceutical preparations for use in the treatment of cerebrovascular accident or stroke; inhalers filled with pharmaceutical preparations for use in the treatment of traumatic brain injury; inhalers filled with pharmaceutical preparations for use in the treatment of cancer; inhalers filled with pharmaceutical preparations for use in the treatment of nausea; inhalers filled with pharmaceutical preparations for use in the treatment of post-traumatic stress disorder; inhalers filled with pharmaceutical preparations for use in the treatment of amyotrophic lateral sclerosis; inhalers filled with pharmaceutical preparations for use in the treatment of chronic pain; inhalers filled with pharmaceutical preparations for use in the treatment of insomnia; inhalers filled with pharmaceutical preparations for use in the relief of pain; inhalers filled with pharmaceutical preparations for use in the treatment of cough or sore throat; inhalers filled with pharmaceutical preparations for use in the treatment of candida infection; inhalers filled with pharmaceutical preparations for use in anti-fungal treatment; inhalers filled with pharmaceutical preparations for use in sedation; inhalers filled with pharmaceutical preparations for use in hormone replacement therapy; inhalers filled with pharmaceutical preparations for use in the treatment of psychosis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of respiratory diseases, disorders and infections; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of asthma; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of chronic obstructive pulmonary disease; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of rhinitis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of sinus polyps; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of viral airway infections; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of multiple sclerosis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of depression; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of epilepsy; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of migraine; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of Alzheimer's disease; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of Parkinson's disease; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of cerebrovascular accident or stroke; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of traumatic brain injury; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of cancer; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of nausea; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of post-traumatic stress disorder; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of amyotrophic lateral sclerosis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of chronic pain; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of insomnia; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the relief of pain; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of cough or sore throat; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of candida infection; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in anti-fungal treatment; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in sedation; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in hormone replacement therapy; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of psychosis; inhalers used to deliver therapeutic agents, namely, analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, or antipsychotics; drug delivery devices, namely, breath actuated nasal delivery devices used to deliver therapeutic agents, namely, analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, or antipsychotics; inhalers filled with analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, respiratory therapeutic agents, or antipsychotics; drug delivery devices, namely, breath actuated nasal delivery devices filled with analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, respiratory therapeutic agents, or antipsychotics; none of the foregoing containing cannabis or CBD

Medical apparatus and instruments, namely, inhalers, sold empty, for therapeutic use; medical apparatus and instruments, namely, breath actuated nasal drug delivery devices, sold empty, for therapeutic use; none of the foregoing for use with cannabis or CBD

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Apr 30, 2026 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Apr 30, 2026 ABN2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jan 14, 2026 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jan 14, 2026 GNSI
SUSPENSION INQUIRY WRITTEN
Jan 14, 2026 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Sep 17, 2025 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 16, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 16, 2025 GNSL
SUSPENSION LETTER WRITTEN
Mar 16, 2025 CNSL
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 14, 2025 CHAN
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 14, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 14, 2025 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Mar 13, 2025 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Dec 27, 2024 GNS2
INQUIRY TO SUSPENSION E-MAILED
Dec 27, 2024 GNSI
SUSPENSION INQUIRY WRITTEN
Dec 27, 2024 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Feb 7, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Feb 7, 2024 GNSL
SUSPENSION LETTER WRITTEN
Feb 7, 2024 CNSL
ASSIGNED TO EXAMINER
Feb 2, 2024 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 30, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 30, 2024 CRFA
ASSIGNED TO LIE
Jan 30, 2024 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 15, 2023 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Nov 15, 2022 GNS2
INQUIRY TO SUSPENSION E-MAILED
Nov 15, 2022 GNSI
SUSPENSION INQUIRY WRITTEN
Nov 15, 2022 CNSI
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 28, 2022 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Oct 28, 2022 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 28, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 28, 2022 REAP
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
May 18, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
May 18, 2022 GNSL
SUSPENSION LETTER WRITTEN
May 18, 2022 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
May 18, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 18, 2022 CRFA
ASSIGNED TO LIE
May 11, 2022 ALIE
NOTICE OF REVIVAL - E-MAILED
May 10, 2022 NREV
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 9, 2022 TROA
PETITION TO REVIVE-GRANTED
May 9, 2022 PETG
TEAS PETITION TO REVIVE RECEIVED
May 9, 2022 PROA
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
May 3, 2022 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
May 3, 2022 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
May 3, 2022 ABN2
ASSIGNED TO EXAMINER
May 3, 2022 DOCK
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Oct 5, 2021 GNS2
INQUIRY TO SUSPENSION E-MAILED
Oct 5, 2021 GNSI
SUSPENSION INQUIRY WRITTEN
Oct 5, 2021 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Sep 1, 2021 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jan 8, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
Jan 8, 2021 GNSL
SUSPENSION LETTER WRITTEN
Jan 8, 2021 CNSL
EXAMINER'S AMENDMENT ENTERED
Jan 5, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 5, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 5, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 5, 2021 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 14, 2020 GNRN
NON-FINAL ACTION E-MAILED
Sep 14, 2020 GNRT
NON-FINAL ACTION WRITTEN
Sep 14, 2020 CNRT
ASSIGNED TO EXAMINER
Sep 14, 2020 DOCK
ASSIGNED TO EXAMINER
Jun 17, 2020 DOCK
ASSIGNED TO EXAMINER
Jun 2, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 18, 2020 NWOS
NEW APPLICATION ENTERED
Mar 14, 2020 NWAP